# For Investors & Partners

> **Business case, market opportunity, and defensibility.**

---

## Executive Summary

**Ternary VAE** is a novel AI platform for predicting drug resistance and immune escape across infectious diseases and cancer.

### Key Differentiators

1. **Novel geometry**: Hyperbolic + p-adic (no direct competitors)
2. **Multi-disease**: 11 disease domains with unified framework
3. **Clinical-grade**: Uncertainty quantification for decision support
4. **Validated**: r=0.89 correlation on HIV (23 drugs)

---

## Market Opportunity

### Drug Resistance Testing

| Segment | TAM | Growth |
|:--------|:----|:-------|
| HIV resistance testing | $2.1B | 8.5% CAGR |
| MDR-TB diagnostics | $0.9B | 12% CAGR |
| Cancer companion dx | $4.2B | 11% CAGR |
| Total addressable | $7.2B | 10% CAGR |

### Key Trends

- Rising antimicrobial resistance (WHO priority)
- Personalized medicine adoption
- AI-enabled diagnostics regulatory pathways (FDA)

---

## Product Vision

### Phase 1: HIV Resistance (Now)

- Predict resistance to 23 ARVs
- Integrate with Stanford HIVDB
- Clinical decision support

### Phase 2: Multi-Disease (2025)

- Tuberculosis MDR/XDR
- SARS-CoV-2 escape
- Influenza vaccine strain selection

### Phase 3: Platform (2026)

- API for pharma partners
- Vaccine design tools
- Novel target discovery

---

## Defensibility

### Intellectual Property

| Asset | Status | Protection |
|:------|:-------|:-----------|
| Hyperbolic VAE architecture | Developed | Trade secret |
| P-adic codon encoding | Novel | Patent pending |
| Multi-disease transfer | Novel | Trade secret |
| Training data pipelines | Developed | Copyright |

### Technical Moat

1. **Mathematical foundation**: Requires PhD-level expertise
2. **Training data**: 200K+ curated HIV sequences
3. **Validation**: Published benchmarks

---

## Traction

### Technical Milestones

| Milestone | Date | Status |
|:----------|:-----|:-------|
| HIV resistance prediction | 2025-12-27 | Complete |
| Multi-disease framework | 2025-12-28 | Complete |
| Uncertainty quantification | 2025-12-28 | Complete |
| Transfer learning | 2025-12-28 | Complete |

### Key Metrics

- 23 drugs validated (HIV)
- r=0.89 mean correlation
- 387 vaccine candidates ranked
- 11 diseases supported

---

## Business Model

### Revenue Streams

1. **SaaS Platform**: Per-test pricing for clinical labs
2. **API Access**: Pharma drug development
3. **Consulting**: Custom model development
4. **Licensing**: Technology licensing

### Unit Economics (Projected)

| Metric | Value |
|:-------|:------|
| Price per test | $50-200 |
| Gross margin | 80%+ |
| CAC payback | <12 months |

---

## Team

See [AUTHORS.md](../../../../LEGAL_AND_IP/AUTHORS.md)

---

## Ask

### Funding Round

- Stage: Seed
- Amount: $2-3M
- Use of funds: Clinical validation, regulatory, team

### Contact

- Email: support@aiwhisperers.com
- GitHub: [Ai-Whisperers](https://github.com/Ai-Whisperers)

---

_Last updated: 2025-12-28_
